{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:50:48Z","timestamp":1794588648284,"version":"4.9.1"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103693"],"award-info":[{"award-number":["82103693"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007620","name":"Department of Education of Liaoning Province","doi-asserted-by":"publisher","award":["LJKZ0787"],"award-info":[{"award-number":["LJKZ0787"]}],"id":[{"id":"10.13039\/501100007620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010031","name":"Postdoctoral Research Foundation of China","doi-asserted-by":"publisher","award":["2022M713486"],"award-info":[{"award-number":["2022M713486"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","award":["202310159006"],"award-info":[{"award-number":["202310159006"]}],"id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","award":["S202310159008"],"award-info":[{"award-number":["S202310159008"]}],"id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","award":["2023JH2\/20200103"],"award-info":[{"award-number":["2023JH2\/20200103"]}],"id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.biopha.2024.117557","type":"journal-article","created":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T09:20:33Z","timestamp":1728811233000},"page":"117557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington\u2019s disease treatment"],"prefix":"10.1016","volume":"180","author":[{"given":"Jia-yuan","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-ru","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5276-7081","authenticated-orcid":false,"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.117557_bib1","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"18","key":"10.1016\/j.biopha.2024.117557_bib2","doi-asserted-by":"crossref","first-page":"e2101","DOI":"10.1212\/WNL.0000000000007147","article-title":"Clinical manifestations of homozygote allele carriers in Huntington disease","volume":"92","author":"Cubo","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.biopha.2024.117557_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/089198879801100204","article-title":"Huntington disease: clinical, genetic, and social aspects","volume":"11","author":"Nance","year":"1998","journal-title":"J. Geriatr. Psychiatry Neurol."},{"issue":"9557","key":"10.1016\/j.biopha.2024.117557_bib4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington's disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2024.117557_bib5","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ng0893-398","article-title":"The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease","volume":"4","author":"Andrew","year":"1993","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.biopha.2024.117557_bib6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1212\/WNL.0b013e318249f683","article-title":"CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion","volume":"78","author":"Lee","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.biopha.2024.117557_bib7","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","article-title":"CAG repeat not polyglutamine length determines timing of Huntington's disease onset","volume":"178","author":"Lee","year":"2019","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.biopha.2024.117557_bib8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","article-title":"Huntingtin lowering strategies for disease modification in huntington's disease","volume":"101","author":"Tabrizi","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2024.117557_bib9","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3390\/cells9061514","article-title":"Huntington's disease-an outlook on the interplay of the HTT protein, microtubules and actin cytoskeletal components","volume":"9","author":"Taran","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2024.117557_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101385","article-title":"Gene targeting techniques for Huntington's disease","volume":"70","author":"Fields","year":"2021","journal-title":"Ageing Res. Rev."},{"issue":"10","key":"10.1016\/j.biopha.2024.117557_bib11","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/14737175.2019.1631161","article-title":"Emerging therapies in Huntington\u2019s disease","volume":"19","author":"Bashir","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.biopha.2024.117557_bib12","first-page":"764","article-title":"Huntingtin-lowering therapies for huntington disease: a review of the evidence of potential benefits and risks","volume":"77","author":"Leavitt","year":"2020","journal-title":"JAMA\u00a0Neurol."},{"key":"10.1016\/j.biopha.2024.117557_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/JHD-229002","article-title":"Huntington's disease clinical trials corner: april 2022","volume":"11","author":"Estevez-Fraga","year":"2022","journal-title":"J. Huntingt. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2024.117557_bib14","article-title":"J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I\/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington\u2019s disease (HD)","volume":"93","author":"Stimming","year":"2022","journal-title":"J. Neurol. Neurosur. Ps"},{"issue":"5","key":"10.1016\/j.biopha.2024.117557_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/17460441.2023.2201493","article-title":"Animal models of Huntington\u2019s disease and their applicability to novel drug discovery and development","volume":"18","author":"Upadhayay","year":"2023","journal-title":"Expert. Opin. Drug. Discov."},{"issue":"1","key":"10.1016\/j.biopha.2024.117557_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-170235","article-title":"Is huntingtin dispensable in the adult brain","volume":"6","author":"Liu","year":"2017","journal-title":"J. Huntingt. Dis."},{"issue":"9","key":"10.1016\/j.biopha.2024.117557_bib17","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202402571","article-title":"Global huntingtin knockout in adult mice leads to fatal neurodegeneration that spares the pancreas","volume":"7","author":"Bragg","year":"2024","journal-title":"Life. Sci. Alliance"},{"key":"10.1016\/j.biopha.2024.117557_bib18","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/cdd.2015.80","article-title":"Primary cilia and autophagic dysfunction in Huntington's disease","volume":"22","author":"Kaliszewski","year":"2015","journal-title":"Cell. Death. Differ."},{"key":"10.1016\/j.biopha.2024.117557_bib19","unstructured":"F. Saudou, S. Humbert, 2016, , Biol. Hunt. Neuron 89910\u2013926, 10.1016\/j.jconrel.2016.09.011."},{"key":"10.1016\/j.biopha.2024.117557_bib20","doi-asserted-by":"crossref","first-page":"a024240","DOI":"10.1101\/cshperspect.a024240","article-title":"Huntington's disease: mechanisms of pathogenesis and therapeutic strategies","volume":"7","author":"Jimenez-Sanchez","year":"2017","journal-title":"Cold. Spring Harb. Perspect. Med."},{"key":"10.1016\/j.biopha.2024.117557_bib21","first-page":"1679","article-title":"Investigational treatments for neurodegenerative diseases caused by inheritance of gene mutations: lessons from recent clinical trials","volume":"18","author":"Imbimbo","year":"2023","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.biopha.2024.117557_bib22","article-title":"Huntingtin is essential for synaptic plasticity in the adult hippocampus","volume":"10","author":"Barron","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2024.117557_bib23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/81593","article-title":"Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice","volume":"26","author":"Dragatsis","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2024.117557_bib24","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1093\/hmg\/10.22.2515","article-title":"The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin","volume":"10","author":"Auerbach","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.biopha.2024.117557_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1242\/dmm.000653","article-title":"Inactivation of Drosophila Huntingtin affects long-term adult functioning and the pathogenesis of a Huntington's disease model","volume":"2","author":"Zhang","year":"2009","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.biopha.2024.117557_bib26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.nbd.2016.09.006","article-title":"Postnatal and adult consequences of loss of huntingtin during development: implications for Huntington's disease","volume":"96","author":"Arteaga-Bracho","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2024.117557_bib27","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1523\/JNEUROSCI.2443-18.2018","article-title":"Loss-of-Huntingtin in medial and lateral ganglionic lineages differentially disrupts regional interneuron and projection neuron subtypes and promotes Huntington's disease-associated behavioral, cellular, and pathological hallmarks","volume":"39","author":"Mehler","year":"2019","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2024.117557_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/science.abq5011","article-title":"Treating early postnatal circuit defect delays Huntington's disease onset and pathology in mice","volume":"377","author":"Braz","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2024.117557_bib29","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12035-015-9662-8","article-title":"Huntington's disease: relationship between phenotype and genotype","volume":"54","author":"Sun","year":"2017","journal-title":"Mol. Neurobiol."},{"issue":"11","key":"10.1016\/j.biopha.2024.117557_bib30","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/mt.2015.128","article-title":"Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in Huntington disease patients of European ancestry","volume":"23","author":"Kay","year":"2015","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2024.117557_bib31","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.ajhg.2019.10.011","article-title":"A comprehensive haplotype-targeting strategy for allele-specific HTT suppression in huntington disease","volume":"105","author":"Kay","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.biopha.2024.117557_bib32","series-title":"In Huntington's Disease","first-page":"571","article-title":"Current clinical trials of new therapeutic agents for Huntington's disease","author":"Leavitt","year":"2024"},{"issue":"7","key":"10.1016\/j.biopha.2024.117557_bib33","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.7150\/thno.43298","article-title":"Allele-specific genome targeting in the development of precision medicine","volume":"10","author":"Wu","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2024.117557_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature13011","article-title":"DNA interrogation by the CRISPR RNA-guided endonuclease Cas9","volume":"507","author":"Sternberg","year":"2014","journal-title":"Nature"},{"issue":"7561","key":"10.1016\/j.biopha.2024.117557_bib35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature14592","article-title":"Engineered CRISPR-Cas9 nucleases with altered PAM specificities","volume":"523","author":"Kleinstiver","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2024.117557_bib36","first-page":"4566","article-title":"Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR\/Cas9","volume":"25","author":"Shin","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.biopha.2024.117557_bib37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 editing of the mutant huntingtin allele in vitro and in vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.biopha.2024.117557_bib38","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nrneurol.2016.151","article-title":"Selective deactivation of huntington disease mutant allele by crispr\u2013cas9 gene editing","volume":"12","author":"Malkki","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"W1","key":"10.1016\/j.biopha.2024.117557_bib39","doi-asserted-by":"crossref","first-page":"W29","DOI":"10.1093\/nar\/gkae419","article-title":"AlPaCas: allele-specific CRISPR gene editing through a protospacer-adjacent-motif (PAM) approach","volume":"52","author":"Rosignoli","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"1-2","key":"10.1016\/j.biopha.2024.117557_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/hum.2020.323","article-title":"Allele-specific knockdown of mutant huntingtin protein via editing at coding region single nucleotide polymorphism heterozygosities","volume":"33","author":"Oikemus","year":"2022","journal-title":"Hum. Gene. Ther."},{"issue":"19","key":"10.1016\/j.biopha.2024.117557_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141042","article-title":"Allele-specific silencing of the gain-of-function mutation in Huntington\u2019s disease using CRISPR\/Cas9","volume":"7","author":"Shin","year":"2022","journal-title":"Jci. Insight"},{"key":"10.1016\/j.biopha.2024.117557_bib42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.omtm.2022.08.005","article-title":"PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington's disease","volume":"26","author":"Shin","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biopha.2024.117557_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fnins.2018.00075","article-title":"Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases","volume":"12","author":"Dabrowska","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.biopha.2024.117557_bib44","article-title":"I05 CRISPR-Cas9 nickase-mediated gene editing to treat Huntington\u2019s disease","author":"Murillo","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biopha.2024.117557_bib45","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.stemcr.2017.01.022","article-title":"Reversal of phenotypic abnormalities by CRISPR\/Cas9-mediated gene correction in Huntington disease patient-derived induced pluripotent stem cells","volume":"8","author":"Xu","year":"2017","journal-title":"Stem. Cell. Rep."},{"key":"10.1016\/j.biopha.2024.117557_bib46","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41551-023-01007-3","article-title":"Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington\u2019s disease","volume":"7","author":"Yan","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.biopha.2024.117557_bib47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fnmol.2016.00070","article-title":"The development of a viral mediated CRISPR\/Cas9 system with doxycycline dependent gRNA expression for inducible in vitro and in vivo genome editing","volume":"9","author":"de Solis","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.biopha.2024.117557_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202201740","article-title":"Delivering the promise of gene therapy with nanomedicines in treating central nervous system diseases","volume":"9","author":"Luo","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biopha.2024.117557_bib49","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2024.117557_bib50","article-title":"I07\u2005Allele specific gene editing for huntington\u2019s disease mediated by the KAMICAS9 self-inactivating CRISPR\/CAS9 system","author":"Deglon","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biopha.2024.117557_bib51","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1038\/d41586-018-05177-y","article-title":"CRISPR takes on Huntington's disease","volume":"557","author":"Eisenstein","year":"2018","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2024.117557_bib52","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00109-020-01893-z","article-title":"Mitigating off-target effects in CRISPR\/Cas9-mediated in vivo gene editing","volume":"98","author":"Han","year":"2020","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.biopha.2024.117557_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202370210","article-title":"A specific mini-intrabody mediates lysosome degradation of mutant huntingtin","volume":"10","author":"Li","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biopha.2024.117557_bib54","doi-asserted-by":"crossref","first-page":"6926","DOI":"10.1038\/srep06926","article-title":"Efficient bi-allelic gene knockout and site-specific knock-in mediated by TALENs in pigs","volume":"4","author":"Yao","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.117557_bib55","doi-asserted-by":"crossref","first-page":"12257","DOI":"10.1021\/bi801800k","article-title":"Enhanced cleavage of double-stranded DNA by artificial zinc-finger nuclease sandwiched between two zinc-finger proteins","volume":"47","author":"Mineta","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2024.117557_bib56","doi-asserted-by":"crossref","first-page":"E3136","DOI":"10.1073\/pnas.1206506109","article-title":"Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice","volume":"109","author":"Garriga-Canut","year":"2012","journal-title":"Proc. Natl. Acad. Sci. Usa."},{"key":"10.1016\/j.biopha.2024.117557_bib57","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","article-title":"Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease","volume":"25","author":"Zeitler","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2024.117557_bib58","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-biochem-013118-111730","article-title":"Evaluating and enhancing target specificity of gene-editing nucleases and deaminases","volume":"88","author":"Kim","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.biopha.2024.117557_bib59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.addr.2020.09.004","article-title":"Non-viral strategies for delivering genome editing enzymes","volume":"168","author":"Li","year":"2021","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.biopha.2024.117557_bib60","article-title":"Engineering gene therapy: advances and barriers","volume":"4","author":"Shahryari","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.biopha.2024.117557_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095611","article-title":"Highly specific contractions of a single CAG\/CTG trinucleotide repeat by TALEN in yeast","volume":"9","author":"Richard","year":"2014","journal-title":"PloS. One"},{"key":"10.1016\/j.biopha.2024.117557_bib62","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3727\/096368916X690863","article-title":"Allele-specific reduction of the mutant huntingtin allele using transcription activator-like effectors in human huntington's disease fibroblasts","volume":"25","author":"Fink","year":"2016","journal-title":"Cell. Transplant."},{"issue":"7","key":"10.1016\/j.biopha.2024.117557_bib63","first-page":"1472","article-title":"Mitochondria in Huntington\u2019s disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies","volume":"18","author":"Jurcau","year":"2023","journal-title":"NRR"},{"key":"10.1016\/j.biopha.2024.117557_bib64","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41588-019-0575-8","article-title":"A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo","volume":"52","author":"Nakamori","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2024.117557_bib65","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/asia.201600527","article-title":"Naphthyridine-benzoazaquinolone: evaluation of a tricyclic system for the binding to (CAG)n repeat DNA and RNA","volume":"11","author":"Li","year":"2016","journal-title":"Chem. Asian J."},{"key":"10.1016\/j.biopha.2024.117557_bib66","doi-asserted-by":"crossref","first-page":"20170077","DOI":"10.1098\/rstb.2017.0077","article-title":"The past and presence of gene targeting: from chemicals and DNA via proteins to RNA","volume":"373","author":"Geel","year":"2018","journal-title":"Philos. Trans. R. Soc. Lond. B. Biol. Sci."},{"key":"10.1016\/j.biopha.2024.117557_bib67","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/jpet.122.001234","article-title":"RNAi-based therapeutics and novel RNA bioengineering Technologies","volume":"384","author":"Traber","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2024.117557_bib68","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.gt.3302356","article-title":"siRNA therapeutics: big potential from small RNAs","volume":"12","author":"Ryther","year":"2005","journal-title":"Gene. Ther."},{"key":"10.1016\/j.biopha.2024.117557_bib69","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.117557_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2024.117557_bib71","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ymthe.2018.02.002","article-title":"Translation of MicroRNA-based huntingtin-lowering therapies from preclinical studies to the clinic","volume":"26","author":"Miniarikova","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2024.117557_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.7","article-title":"Artificial miRNAs targeting mutant huntingtin show preferential silencing in vitro and in vivo. molecular therapy","volume":"4","author":"Monteys","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2024.117557_bib73","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.2174\/138161209789649295","article-title":"RNAi applications in therapy development for neurodegenerative disease","volume":"15","author":"Maxwell","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2024.117557_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.7","article-title":"Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for huntington's disease","volume":"5","author":"Miniarikova","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2024.117557_bib75","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","article-title":"AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease","volume":"24","author":"Miniarikova","year":"2017","journal-title":"Gene. Ther."},{"key":"10.1016\/j.biopha.2024.117557_bib76","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtn.2022.04.031","article-title":"A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease","volume":"28","author":"Kotowska-Zimmer","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2024.117557_bib77","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00018-020-03596-7","article-title":"Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts","volume":"78","author":"Ciesiolka","year":"2021","journal-title":"Cell. Mol. Life. Sci."},{"key":"10.1016\/j.biopha.2024.117557_bib78","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrd3010","article-title":"Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application","volume":"9","author":"Jackson","year":"2010","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2024.117557_bib79","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(04)00678-7","article-title":"Molecular medicine for the brain: silencing of disease genes with RNA interference","volume":"3","author":"Davidson","year":"2004","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2024.117557_bib80","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.drudis.2014.09.011","article-title":"Delivering a disease-modifying treatment for Huntington's disease","volume":"20","author":"Godinho","year":"2015","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.biopha.2024.117557_bib81","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1021\/acs.molpharmaceut.0c01238","article-title":"Advances in the design of (Nano)formulations for delivery of antisense oligonucleotides and small interfering RNA: focus on the central nervous system","volume":"18","author":"Mendon\u00e7a","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2024.117557_bib82","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1016\/j.ymthe.2006.08.790","article-title":"711. allele-specific silencing of mutant huntingtin for huntington's disease therapy","volume":"13","author":"Mas-Monteys","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2024.117557_bib83","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1089\/hum.2007.116","article-title":"Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts","volume":"19","author":"van Bilsen","year":"2008","journal-title":"Hum. Gene. Ther."},{"key":"10.1016\/j.biopha.2024.117557_bib84","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"Hu","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2024.117557_bib85","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1471-4159.2008.05734.x","article-title":"Allele-specific silencing of mutant Huntington's disease gene","volume":"108","author":"Zhang","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2024.117557_bib86","doi-asserted-by":"crossref","first-page":"12069","DOI":"10.1093\/nar\/gkab1126","article-title":"Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity","volume":"49","author":"Yamada","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2024.117557_bib87","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1038\/s41467-022-33061-x","article-title":"Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2024.117557_bib88","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.chembiol.2010.10.013","article-title":"Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism","volume":"17","author":"Hu","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.biopha.2024.117557_bib89","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1093\/nar\/gkr156","article-title":"Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats","volume":"39","author":"Fiszer","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2024.117557_bib90","doi-asserted-by":"crossref","first-page":"11270","DOI":"10.1093\/nar\/gks907","article-title":"Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway","volume":"40","author":"Hu","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2024.117557_bib91","doi-asserted-by":"crossref","first-page":"10426","DOI":"10.1093\/nar\/gkt825","article-title":"Self-duplexing CUG repeats selectively inhibit mutant huntingtin expression","volume":"41","author":"Fiszer","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2024.117557_bib92","doi-asserted-by":"crossref","first-page":"8788","DOI":"10.1093\/nar\/gkt594","article-title":"RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression","volume":"41","author":"Liu","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2024.117557_bib93","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","article-title":"Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.117557_bib94","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","article-title":"A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference","volume":"217","author":"Lombardi","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.biopha.2024.117557_bib95","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients","volume":"19","author":"Pfister","year":"2009","journal-title":"Curr. Biol."},{"key":"10.1016\/j.biopha.2024.117557_bib96","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/mt.2008.231","article-title":"Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2024.117557_bib97","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40035-017-0101-9","article-title":"RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA","volume":"6","author":"Aguiar","year":"2017","journal-title":"Transl. Neurodegener."},{"issue":"3","key":"10.1016\/j.biopha.2024.117557_bib98","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(04)00678-7","article-title":"Molecular medicine for the brain: silencing of disease genes with RNA interference","volume":"3","author":"Davidson","year":"2004","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2024.117557_bib99","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2174\/1566523215666150812115730","article-title":"Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfalls","volume":"15","author":"Trochet","year":"2015","journal-title":"Curr. Gene. Ther."},{"key":"10.1016\/j.biopha.2024.117557_bib100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099341","article-title":"Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells","volume":"9","author":"Drouet","year":"2014","journal-title":"PloS. One"},{"key":"10.1016\/j.biopha.2024.117557_bib101","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.omtn.2019.12.012","article-title":"Universal RNAi Triggers for the Specific Inhibition of Mutant Huntingtin, Atrophin-1, Ataxin-3, and Ataxin-7 Expression","volume":"19","author":"Kotowska-Zimmer","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2024.117557_bib102","series-title":"Neurobiology of Huntington's Disease: Applications to Drug Discovery","article-title":"RNA-and DNA-based therapies for Huntington\u2019s disease","author":"Meghan","year":"2011"},{"key":"10.1016\/j.biopha.2024.117557_bib103","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.biopha.2024.117557_bib104","series-title":"Gapmers: Methods and Protocols","first-page":"3","article-title":"Invention and early history of gapmers","author":"Lim","year":"2020"},{"key":"10.1016\/j.biopha.2024.117557_bib105","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/brain\/awz328","article-title":"Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders","volume":"143","author":"Silva","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2024.117557_bib106","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene \/ allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2024.117557_bib107","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar3959","article-title":"Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease","volume":"10","author":"Southwell","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2024.117557_bib108","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/bi101208k","article-title":"Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat","volume":"49","author":"Gagnon","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2024.117557_bib109","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS","volume":"41","author":"\u00d8stergaard","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.biopha.2024.117557_bib110","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/brain\/awz328","article-title":"Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders","volume":"143","author":"Silva","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2024.117557_bib111","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene \/ allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2024.117557_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107434","article-title":"Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients","volume":"9","author":"Skotte","year":"2014","journal-title":"PloS. One"},{"key":"10.1016\/j.biopha.2024.117557_bib113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171127","article-title":"The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain","volume":"12","author":"Datson","year":"2017","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2024.117557_bib114","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/mt.2014.153","article-title":"In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides","volume":"22","author":"Southwell","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2024.117557_bib115","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1002\/med.21706","article-title":"Therapeutic antisense oligonucleotides for movement disorders","volume":"41","author":"Doxakis","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.biopha.2024.117557_bib116","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1146\/annurev-pharmtox-010919-023738","article-title":"Antisense drugs make sense for neurological diseases","volume":"61","author":"Bennett","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2024.117557_bib117","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1093\/hmg\/ddu349","article-title":"Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity","volume":"23","author":"Sun","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.biopha.2024.117557_bib118","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/j.1745-7254.2006.00410.x","article-title":"Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies","volume":"27","author":"Wang","year":"2006","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.biopha.2024.117557_bib119","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrn3570","article-title":"Choosing an animal model for the study of Huntington's disease","volume":"14","author":"Pouladi","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.biopha.2024.117557_bib120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1749-6632.2009.04975.x","article-title":"Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA","volume":"1175","author":"Hu","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2024.117557_bib121","article-title":"I06 Allele-selective inhibition of mutant htt transcription throughout the brain after subcutaneous administration of a patrol\u2122-enabled investigational genetic therapy in the r6\/2 Huntington's disease transgenic mouse model","author":"Friedlander","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biopha.2024.117557_bib122","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/molecules27020536","article-title":"Small drugs, huge impact: the extraordinary impact of antisense oligonucleotides in research and drug development","volume":"27","author":"Quemener","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2024.117557_bib123","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","article-title":"Antisense oligonucleotides in therapy for neurodegenerative disorders","volume":"87","author":"Evers","year":"2015","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.biopha.2024.117557_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1074-5521(00)00058-2","article-title":"Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA","volume":"8","author":"Braasch","year":"2001","journal-title":"Chem. Biol."},{"key":"10.1016\/j.biopha.2024.117557_bib125","series-title":"Gapmers: Methods and Protocols","first-page":"49","article-title":"Knocking down long noncoding RNAs using antisense oligonucleotide gapmers","author":"Maruyama","year":"2020"},{"key":"10.1016\/j.biopha.2024.117557_bib126","first-page":"1975","article-title":"Differential effects on allele selective silencing of mutant huntingtin by two stereoisomers of \u03b1,\u03b2-constrained nucleic acid","volume":"9","author":"\u00d8stergaard","year":"2014","journal-title":"ACS\u00a0Chem. Biol."},{"key":"10.1016\/j.biopha.2024.117557_bib127","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omtn.2017.02.001","article-title":"Fluorinated nucleotide modifications modulate allele selectivity of SNP-targeting antisense oligonucleotides","volume":"7","author":"\u00d8stergaard","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2024.117557_bib128","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1016\/j.bmcl.2009.09.004","article-title":"Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy)phenyl] pyrrolocytosine","volume":"19","author":"Hu","year":"2009","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2024.117557_bib129","doi-asserted-by":"crossref","first-page":"8404","DOI":"10.1021\/ja200312y","article-title":"Antisense and antigene inhibition of gene expression by cell-permeable oligonucleotide-oligospermine conjugates","volume":"133","author":"Gagnon","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2024.117557_bib130","series-title":"Gapmers: Methods and Protocols","first-page":"57","article-title":"Development of antisense oligonucleotide gapmers for the treatment of Huntington\u2019s disease","author":"Aslesh","year":"2020"},{"key":"10.1016\/j.biopha.2024.117557_bib131","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000323","article-title":"Antisense oligonucleotides: a primer","volume":"5","author":"Scoles","year":"2019","journal-title":"Neurol. Genet."},{"issue":"6","key":"10.1016\/j.biopha.2024.117557_bib132","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","article-title":"The CREST-E study of creatine for Huntington disease: a randomized controlled trial","volume":"89","author":"Hersch","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2024.117557_bib133","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41587-021-00955-y","article-title":"Questions swirl around failures of disease-modifying Huntington's drugs","volume":"39","author":"Sheridan","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2024.117557_bib134","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40259-022-00519-9","article-title":"Antisense oligonucleotide therapy: from design to the Huntington disease clinic","volume":"36","author":"Rook","year":"2022","journal-title":"BioDrugs"},{"issue":"7","key":"10.1016\/j.biopha.2024.117557_bib135","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117557_bib136","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/d41573-021-00088-6","article-title":"Double setback for ASO trials in Huntington disease","volume":"20","author":"Kingwell","year":"2021","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2024.117557_bib137","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd.2018.93","article-title":"Principles for targeting RNA with drug-like small molecules","volume":"17","author":"Warner","year":"2018","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2024.117557_bib138","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.biochi.2019.05.001","article-title":"Rationally designed small molecules targeting toxic CAG repeat RNA that causes Huntington's disease (HD) and spinocerebellar ataxia (SCAs)","volume":"163","author":"Khan","year":"2019","journal-title":"Biochimie"},{"key":"10.1016\/j.biopha.2024.117557_bib139","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1021\/acschembio.7b00699","article-title":"Myricetin reduces toxic level of CAG repeats RNA in Huntington's disease (HD) and spino cerebellar ataxia (SCAs)","volume":"13","author":"Khan","year":"2018","journal-title":"Acs. Chem. Biol."},{"key":"10.1016\/j.biopha.2024.117557_bib140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53410-z","article-title":"Discovery of a potent small molecule inhibiting Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein","volume":"9","author":"Khan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.117557_bib141","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41593-022-01207-1","article-title":"An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models","volume":"26","author":"Morelli","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.biopha.2024.117557_bib142","first-page":"2022","article-title":"RNA-targeting CRISPR\/Cas13d system eliminates disease-related phenotypes in pre-clinical models of huntington's disease","volume":"01","author":"Morelli","year":"2022","journal-title":"BioRxiv"},{"key":"10.1016\/j.biopha.2024.117557_bib143","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1021\/cr0681546","article-title":"Targeting RNA with small molecules","volume":"108","author":"Thomas","year":"2008","journal-title":"Chem. Rev."},{"key":"10.1016\/j.biopha.2024.117557_bib144","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev-pharmtox-010715-103507","article-title":"Targeted protein degradation by small molecules","volume":"57","author":"Bondeson","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2024.117557_bib145","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.molmed.2021.06.012","article-title":"Breakthroughs and bottlenecks in autophagy research","volume":"27","author":"Mizushima","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.biopha.2024.117557_bib146","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41580-022-00529-z","article-title":"The emerging mechanisms and functions of microautophagy","volume":"24","author":"Wang","year":"2023","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2024.117557_bib147","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41580-018-0001-6","article-title":"The coming of age of chaperone-mediated autophagy","volume":"19","author":"Kaushik","year":"2018","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2024.117557_bib148","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.tcb.2012.05.006","article-title":"Chaperone-mediated autophagy: a unique way to enter the lysosome world","volume":"22","author":"Kaushik","year":"2012","journal-title":"Trends Cell. Biol."},{"key":"10.1016\/j.biopha.2024.117557_bib149","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nchembio.79","article-title":"Novel targets for Huntington's disease in an mTOR-independent autophagy pathway","volume":"4","author":"Williams","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2024.117557_bib150","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cell.2009.03.018","article-title":"Acetylation targets mutant huntingtin to autophagosomes for degradation","volume":"137","author":"Jeong","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.117557_bib151","doi-asserted-by":"crossref","first-page":"839","DOI":"10.18632\/aging.100818","article-title":"Blocking the association of HDAC4 with MAP1S accelerates autophagy clearance of mutant Huntingtin","volume":"7","author":"Yue","year":"2015","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.biopha.2024.117557_bib152","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12017-018-8482-1","article-title":"Correction of Huntington\u2019s disease phenotype by genistein-induced autophagy in the cellular model","volume":"20","author":"Pierzynowska","year":"2018","journal-title":"Neuromolecular. Med."},{"key":"10.1016\/j.biopha.2024.117557_bib153","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT\u2013LC3 linker compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2024.117557_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2021.102114","article-title":"Targeted protein degradation: emerging concepts and protein state-specific targeting principles","volume":"67","author":"Tao","year":"2022","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.biopha.2024.117557_bib155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13578-022-00906-3","article-title":"Discovery of an autophagy inducer J3 to lower mutant huntingtin and alleviate Huntington\u2019s disease-related phenotype","volume":"12","author":"Long","year":"2022","journal-title":"Cell. Biosci."},{"key":"10.1016\/j.biopha.2024.117557_bib156","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2024.117557_bib157","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev-animal-022516-022754","article-title":"Behavioral phenotyping assays for genetic mouse models of neurodevelopmental, neurodegenerative, and psychiatric disorders","volume":"5","author":"Sukoff Rizzo","year":"2017","journal-title":"Annu. Rev. Anim. Biosci."},{"key":"10.1016\/j.biopha.2024.117557_bib158","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.addr.2020.09.004","article-title":"Non-viral strategies for delivering genome editing enzymes","volume":"168","author":"Li","year":"2021","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.biopha.2024.117557_bib159","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1038\/s41467-022-31905-0","article-title":"Compounds activating VCP D1 ATPase enhance both autophagic and proteasomal neurotoxic protein clearance","volume":"13","author":"Wrobel","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2024.117557_bib160","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ymthe.2005.04.003","article-title":"Intrabody applications in neurological disorders: progress and future prospects","volume":"12","author":"Miller","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2024.117557_bib161","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000070","article-title":"Resolution of hepatic fibrosis after ZFN-mediated gene editing in the PiZ mouse model of human \u03b11-antitrypsin deficiency","volume":"7","author":"Li","year":"2023","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.biopha.2024.117557_bib162","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nbt.1608","article-title":"Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein","volume":"28","author":"Bauer","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2024.117557_bib163","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114303119","article-title":"Suppression of toxicity of the mutant huntingtin protein by its interacting compound, desonide","volume":"119","author":"Song","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2024.117557_bib164","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1087057107299428","article-title":"Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments","volume":"12","author":"Coufal","year":"2007","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.biopha.2024.117557_bib165","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/life11070607","article-title":"Chemical-mediated targeted protein degradation in neurodegenerative diseases","volume":"11","author":"Hyun","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.biopha.2024.117557_bib166","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/nrd1578","article-title":"Making protein interactions druggable: targeting PDZ domains","volume":"3","author":"Dev","year":"2004","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2024.117557_bib167","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1073\/pnas.071058398","article-title":"Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease","volume":"98","author":"Lecerf","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2024.117557_bib168","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nbd.2004.11.003","article-title":"A human single-chain Fv intrabody preferentially targets amino-terminal huntingtin fragments in striatal models of Huntington's disease","volume":"19","author":"Miller","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2024.117557_bib169","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1073\/pnas.0505321102","article-title":"Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies","volume":"102","author":"Wolfgang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2024.117557_bib170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029199","article-title":"Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments","volume":"6","author":"Butler","year":"2011","journal-title":"PloS. One"},{"key":"10.1016\/j.biopha.2024.117557_bib171","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1523\/JNEUROSCI.2747-08.2008","article-title":"Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity","volume":"28","author":"Southwell","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2024.117557_bib172","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2024.117557_bib173","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1083\/jcb.200710158","article-title":"Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin","volume":"181","author":"Wang","year":"2008","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.biopha.2024.117557_bib174","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.csbj.2016.07.003","article-title":"Antibodies inside of a cell can change its outside: can intrabodies provide a new therapeutic paradigm?","volume":"14","author":"Marschall","year":"2016","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.biopha.2024.117557_bib175","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s13311-020-00891-w","article-title":"Therapeutic update on Huntington\u2019s disease: symptomatic treatments and emerging disease-modifying therapies","volume":"17","author":"Dash","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.biopha.2024.117557_bib176","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41598-018-37102-8","article-title":"Antagonistic pleiotropy in mice carrying a CAG repeat expansion in the range causing Huntington\u2019s disease","volume":"9","author":"Morton","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.117557_bib177","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/ilar.48.4.356","article-title":"Animal models of Huntington's disease","volume":"48","author":"Ramaswamy","year":"2007","journal-title":"Ilar. J."},{"issue":"1","key":"10.1016\/j.biopha.2024.117557_bib178","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202001238","article-title":"Is viral vector gene delivery more effective using biomaterials","volume":"10","author":"Wang","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.biopha.2024.117557_bib179","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2016.09.011","article-title":"Gene therapy for the CNS using AAVs: the impact of systemic delivery by AAV9","volume":"241","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224014434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224014434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:13:30Z","timestamp":1773969210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224014434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":179,"alternative-id":["S0753332224014434"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117557","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington\u2019s disease treatment","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117557"}}